Public epitope specificity of HLA class I antibodies induced by a failed kidney transplant: Alloantibody characterization by flow cytometric techniques

Transplantation

Volumn 81, Issue 9, 2006, Pages 1298-1305

  Piazza, Antonina ^a,c   Poggi, Elvira ^a   Ozzella, Giuseppina ^a   Borrelli, Laura ^b   Monaco, Palmina I ^a   Scornajenghi, Alessandra ^b   Tisone, Giuseppe ^b   Adorno, Domenico ^b  

^a CNR   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c S EUGENIO HOSPITAL   (Italy)

Author keywords

Alloantibody; Flow cytometry; HLA epitopes; Kidney transplant; Residue matching

Indexed keywords

ALLOANTIBODY; EPITOPE; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN;

ADULT; ALLELE; AMINO ACID SEQUENCE; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; FLOW CYTOMETRY; GRAFT FAILURE; HLA MATCHING; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SERUM;

ANTIBODY SPECIFICITY; ANTIGEN-ANTIBODY REACTIONS; EPITOPES; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-A ANTIGENS; HLA-B ANTIGENS; HUMANS; IMMUNOGLOBULIN G; ISOANTIBODIES; KIDNEY TRANSPLANTATION; REOPERATION; TREATMENT FAILURE;

EID: 33744501000     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000209654.87584.c5     Document Type: Article

References (30)

1. Opelz G. Effect of HLA matching in 10,000 cyclosporine-treated cadaver kidney transplants. Transplant Proc 1987; 19: 641.
2. Takemoto S, Terasaki PI, Cecka JM, et al. Survival of nationally shared, HLA-matched kidney transplants from cadaveric donors. N Engl J Med 1992; 327: 834.
3. Thorogood J, van Houwelingen JC, van Rood JJ, et al. Factors contributing to the long-term kidney graft survival in Eurotransplant. Transplantation 1992; 54: 152.
4. Takemoto S. HLA matching in the new millennium. In: Cecka, JM TerasakiPI, eds. Clinical Transplants 2003. Los Angeles: UCLA Tissue Typing Laboratory, 2004: 387.
5. Fernandez-Fresnedo G, Pastor JM, Ruiz JC, et al. Differences in anti-CREG antibody formation between transplanted and nontransplanted renal patients. Transplantation 1999; 67: 1188.
6. Rodey GE, Revels K, Fuller TC. Epitope specificity of HLA class I alloantibodies. Stability of cross-reactive group antibody patterns over extended time periods. Transplantation 1997; 63: 885.
7. Parham P, Adams EJ, Arnett KL. The origins of HLA-A, B, C polymorphism. Immunol Rev 1995; 145: 141.
8. Rodey GE, Neylan JF, Whelchel JD, et al. Epitope specificity of HLA class I alloantibodies. I.Frequency analysis of antibodies to private versus public specificities in potential transplant recipients. Hum Immunol 1994; 39: 272.
9. El-Awar N, Terasaki PI, Lazda V, et al. Almost all patients who are waiting for a regraft of a kidney transplant have anti-HLA antibodies. Transplant Proc 2002; 34: 2531.
10. Duquesnoy RJ, White LT, Fierst JW, et al. Multiscreen serum analysis of highly sensitized renal dialysis patients for antibodies toward public and private class I HLA determinants. Implication for computer-predicted acceptable and unacceptable donor mismatches in kidney transplantation. Transplantation 1990; 50: 427.
11. Laundy GJ, Bradley BA. The predictive value of epitope analysis in highly sensitized patients awaiting renal transplantation. Transplantation 1995; 59: 1207.
12. Takemoto S, Gjertson DW, Terasaki PI. HLA matching: a comparison of conventional and molecular approaches. In: Terasaki, PI Cecka JM, eds. Clinical Transplants 1992. Los Angeles: UCLA Tissue Typing Laboratory 1993: 413.
13. Thompson JS, Thacker LR. CREG matching for first cadaveric kidney transplants (TNX) performed by SEOPF centers between October 1987 and September 1995. Clin Transplant 1996; 10: 586.
14. Pei R, Lee J-H, Shih N-J, et al. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003; 75: 43.
15. Pei R, Wang G, Tarsitani C, et al. Simultaneous HLA class I and class II antibodies screening with flow cytometry. Hum Immunol 1998; 59: 313.
16. Rodey GE. HLA Beyond Tears. Atlanta: De Novo, Inc., 1991.
17. Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003; 3: 665.
18. Papassavas AC, Iniotaki-Theodoraki A, Boletis J, et al. Epitope analysis of HLA class I donor specific antibodies in sensitized renal transplant recipients. Transplantation 2000; 70: 323.
19. Rodey GE, Neylan JF, Whelchel JD, et al. Epitope specificity of HLA class I alloantibodies. Hum Immunol 1994; 39: 272.
20. Oldfather JW, Mara A, Phelan DL, et al. The occurrence of crossreactive "public" antibodies in the sera of highly sensitized dialysis patients [abstract]. Transplant Proc 1983; 15: 1212.
21. Dankers MKA, Witvliet MD, Roelen DL, et al. The number of amino acid triplet differences between patient and donor is predictive for the antibody reactivity against mismatched human leukocyte antigens. Transplantation 2004; 77: 1236.
22. Park MS, Clark BD, Maruya E, et al. HLA class I epitopes accounted for by single residues. In: Terasaki, PI CeckaJM, eds. Clinical Transplants 1991. Los Angeles: UCLA Tissue Typing Laboratory 1992: 335.
23. van Kampen CA, Versteeg-van der Voort Maarschalk MF, Roelen DL, et al. Rejection of a kidney transplant does not always lead to priming of cytotoxic T cells against mismatched donor HLA class I antigens. Transplantation 2001; 71: 869.
24. Babbitt BP, Matsueda G, Haber E, et al. Antigenic competition at the level of peptide-Ia binding. Proc Natl Acad Sci U S A 1986; 83: 4509.
25. Zhang L, Li SG, Vandekerckhove B, et al. Analysis of cytotoxic T cell precursor frequencies directed against individual HLA-A and -B alloantigens. J Immunol Methods 1989; 121: 39.
26. Maruya E, Takemoto S, Terasaki PI. HLA matching: identification of permissible HLA mismatches. In: Terasaki, PI Cecka JM, eds. Clinical Transplants 1993. Los Angeles, UCLA Tissue Typing Laboratory 1994: 511.
27. Doxiadis UL, Smits JMA, Schreuder GMT, et al. Association between specific HLA combination and probability of kidney allograft loss: the taboo concept. Lancet 1996; 348: 850.
28. Fuller TC, Fuller A. The humoral immune response against an HLA class I allodeterminant correlates with the HLA-DR phenotype of the responder. Transplantation 1999; 68: 173.
29. Papassavas AC, Barnardo MCNM, Bunce M, et al. Is there MHC class II restriction of the response to MHC class I in transplant patients? Transplantation 2002; 73: 642.
30. Dankers MKA, Roelen DL, Nagelkerke NJD, et al. The HLA-DR phenotype of the responder is predictive of humoral response against HLA class I antigens. Hum Immunol 2004; 65: 13.